Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vidofludimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 20/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 8/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 2/20 | 1.00 |
| ▸ | JMJD7 | P0C870 | 1/20 | 1.00 |
| ▸ | NR4A3 | Q92570 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidofludimus SCHEMBL247888 | 1.00 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL28974266 | 0.99 | DHODH (0.98) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL18109121 | 0.94 | DHODH (0.89) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL29869156 | 0.93 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL25834765 | 0.91 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4397456 | 0.91 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL28323370 | 0.90 | DHODH (0.82) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL25839936 | 0.90 | DHODH (0.82) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL3925167 | 0.90 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4389409 | 0.90 | DHODH (0.81) | DHODHNR4A2NR4A1JMJD7NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115166-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12480089-B2 | Antiviral treatment comprising Blis containing probiotic products | BLIS TECHNOLOGIES LIMITED (NL) | 2025-11-25 | — | — | US | claimed |
| WO-2025215126-A1 | SYNTHESIS OF VIDOFLUDIMUS AND ITS CALCIUM SALT | IMMUNIC AG (DE) | 2025-10-16 | — | — | WO | claimed |
| EP-3858361-B1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORP (JP) | 2025-10-08 | — | — | EP | claimed |
| US-20250222109-A1 | STRUCTURED LIPID COMPOSITIONS | THE UNIVERSITY OF BERN (CH) | 2025-07-10 | — | — | US | claimed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-20250136542-A1 | CALCIUM SALT POLYMORPHS AS ANTI-INFLAMMATORY, IMMUNODULATORY AND ANTI-PROLIFERATIVE AGENTS | IMMUNIC AG (DE) | 2025-05-01 | — | — | US | claimed |
| EP-4531834-A1 | TREATMENT OF ULCERATIVE COLITIS COMPRISING VIDOFLUDIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Immunic AG (DE) | 2025-04-09 | — | — | EP | claimed |
| WO-2025036938-A1 | ORAL PHARMACEUTICAL DOSAGE FORM PROVIDING IMMEDIATE RELEASE OF VIDOFLUDIMUS | IMMUNIC AG (DE) | 2025-02-20 | — | — | WO | claimed |
| WO-2022271604-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | claimed |
| CN-115335052-A | Methods and compositions for inhibiting dihydroorotate dehydrogenase in combination with anti-CD 38 therapeutics | 俄亥俄州国家创新基金会 | 2022-11-11 | — | — | CN | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-4081219-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2022-11-02 | — | — | EP | claimed |
| WO-2022200615-A1 | PYRIMIDINE BIOSYNTHESIS INHIBITOR COMBINATION FOR USE IN TREATING VIRAL INFECTIONS | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2022-09-29 | — | — | WO | claimed |
| WO-2022187458-A1 | USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | claimed |
| EP-3892268-B1 | USE OF VIDOFLUDIMUS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | INST NAT SANTE RECH MED (FR) | 2022-08-17 | — | — | EP | claimed |
| WO-2022167402-A1 | METHODS OF THERAPY COMPRISING ADMINISTERING A THERAPEUTICALLY EFFECTIVE COMBINATION COMPRISING A DHODH INHIBITOR AND AN IDH INHIBITOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-11 | — | — | WO | claimed |
| WO-2022076903-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022061266-A1 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-03-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115166-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS | ADRB3, ADRB2, ARRB1 | DHODH 434/4885NR4A2 1260/4885NR4A1 1533/4885 |
| US-20250136542-A1 | CALCIUM SALT POLYMORPHS AS ANTI-INFLAMMATORY, IMMUNODULATORY AND ANTI-PROLIFERATIVE AGENTS | DHODH, CA2, DPYD | DHODH 1/4885NR4A2 3037/4885NR4A1 2666/4885 |
| US-20250222109-A1 | STRUCTURED LIPID COMPOSITIONS | FABP2, MGLL, LIPC | DHODH 2247/4885NR4A2 2201/4885NR4A1 1442/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | DHODH 2908/4885NR4A2 350/4885NR4A1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.